Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Classical hematology 2

Conditions

Myeloproliferative Disorders 3Myelodysplastic Syndromes 2Anemia 2Thrombocytosis 1Primary Myelofibrosis 1Leukemia, Myeloid, Acute 1

Interventions

Darbepoetin alfa 19Epoetin Alfa 17ACE-011 4Cyclosporine 3Busulfan 3luspatercept 2fludarabine phosphate 2fludarabine 2ferric carboxymaltose 2epoetin beta 2continuous erythropoietin receptor activator 2Methotrexate 2Iron-Dextran Complex 2Filgrastim 2Cyclophosphamide 2vactosertib 1thymoglobulin 1ruxolitinib 1roxadustat 1peginesatide 1pegfilgrastim 1niraparib 1leridistim 1iron isomaltoside 1000 1hematide 1ferric gluconate 1eltrombopag 1angiotensin I (1-7) 1Therapeutics 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Anemia × luspatercept × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Celgene

Phase 2 Completed
95 enrolled 32 charts
Classical hematologyMyeloid

Anemia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡